GPOH GEMEINNUTZIGE GMBH

Their core work

GPOH (Gesellschaft für Pädiatrische Onkologie und Hämatologie) is the German Society for Pediatric Oncology and Hematology — a non-profit organization that represents and coordinates Germany's clinical network for childhood and adolescent blood cancers. Their core contribution to research is access to real-world patient data from German pediatric oncology treatment centers, feeding into large-scale European disease registries and data platforms. They participated exclusively in the HARMONY alliance, Europe's flagship public-private effort to build a big data infrastructure for hematological malignancies, covering conditions from childhood leukemia to adult myeloma and myelodysplastic syndromes. In practice, they act as a national clinical data custodian and disease-area expert, bridging frontline pediatric oncology practice with large pan-European research consortia.

What they specialise in

How they've shifted over time

In their first project (HARMONY, 2017–2023), GPOH's focus was disease-specific and data-collection oriented — listing concrete cancer types (leukemia, lymphoma, MDS, multiple myeloma, childhood cancer) alongside real-life patient data and big data platform infrastructure. By HARMONY PLUS (2020–2024), the language shifted toward molecular genetics, translational medicine, digital health outcomes, and business model development, reflecting a maturation from raw data contribution toward scientific interpretation and platform sustainability. The trend is clear: GPOH is moving from being a clinical data supplier to becoming a partner in making sense of that data at the molecular and translational level.

GPOH is evolving from a national clinical data contributor toward a partner capable of engaging in molecular-level translational research and digital health platform governance — making them increasingly relevant for precision oncology and AI-driven diagnosis consortia.

How they like to work

GPOH has participated exclusively as a consortium partner, never as a project coordinator — a pattern consistent with their role as a specialist data contributor rather than a project driver. Both of their projects belong to the same HARMONY family, a very large multi-stakeholder alliance with 57 distinct partners across 13 countries, suggesting GPOH operates within established, long-running collaborative structures rather than initiating their own consortia. For a future collaborator, this means GPOH is reliable and embedded in European hematology networks, but will need a stronger project lead to anchor the consortium around them.

GPOH has built connections with 57 unique consortium partners across 13 countries through just two projects — an unusually broad network for such a small project portfolio, reflecting the scale of the HARMONY alliance. Their European reach likely spans the major pediatric oncology centers, pharmaceutical companies, and health data institutions that make up HARMONY's membership.

What sets them apart

GPOH is the organized voice of German pediatric oncology and hematology, which gives them something no university department or research institute can easily replicate: structured access to clinical data from Germany's network of specialized childhood cancer treatment centers. Their non-profit status and society mandate make them a trusted, neutral data partner — not a commercial entity with conflicting interests — which is particularly valuable in sensitive patient data governance contexts. For any consortium targeting pediatric blood cancers or building pan-European hematology registries, GPOH is the natural German anchor point.

Highlights from their portfolio

• HARMONY
  The flagship project, receiving €751,855 — one of Europe's largest efforts to build a unified big data platform for hematological malignancies, spanning adult and pediatric cancers across multiple countries.
• HARMONY PLUS
  The continuation and expansion of HARMONY that introduced molecular genetics and translational medicine dimensions, showing GPOH's role in scaling the alliance's scientific ambitions beyond data collection.